Moderna Earnings Estimate

MRNA Stock  USD 30.29  0.20  0.66%   
The next projected EPS of Moderna is estimated to be -1.8162 with future projections ranging from a low of -2.4995 to a high of -1.25. Moderna's most recent 12-month trailing earnings per share (EPS TTM) is at -8.73. Please be aware that the consensus of earnings estimates for Moderna is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Moderna is projected to generate -1.8162 in earnings per share on the 30th of September 2025. Moderna earnings estimates show analyst consensus about projected Moderna EPS (Earning Per Share). It derives the highest and the lowest estimates based on Moderna's historical volatility. Many public companies, such as Moderna, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Moderna's earnings estimates, investors can diagnose different trends across Moderna's analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about 3.3 BCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.

Moderna Earnings Estimation Breakdown

The calculation of Moderna's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Moderna is estimated to be -1.8162 with the future projection ranging from a low of -2.4995 to a high of -1.25. Please be aware that this consensus of annual earnings estimates for Moderna is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.0
-2.5
Lowest
Expected EPS
-1.8162
-1.25
Highest

Moderna Earnings Projection Consensus

Suppose the current estimates of Moderna's value are higher than the current market price of the Moderna stock. In this case, investors may conclude that Moderna is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Moderna's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 30th of September 2025Current EPS (TTM)
2672.36%
0.0
-1.8162
-8.73

Moderna Earnings per Share Projection vs Actual

Actual Earning per Share of Moderna refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Moderna predict the company's earnings will be in the future. The higher the earnings per share of Moderna, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Moderna Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Moderna, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Moderna should always be considered in relation to other companies to make a more educated investment decision.

Moderna Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Moderna's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
null
nullnullnullnull
2025-04-30
2025-03-31-3.03-2.520.5116 
2025-02-20
2024-12-31-2.7599-2.91-0.1501
2024-11-07
2024-09-30-1.90.031.93101 
2024-08-01
2024-06-30-3.38-3.330.05
2024-05-02
2024-03-31-3.58-3.070.5114 
2024-02-22
2023-12-31-0.970.551.52156 
2023-11-02
2023-09-30-1.93-9.53-7.6393 
2023-08-03
2023-06-30-4.04-3.620.4210 
2023-05-04
2023-03-31-1.770.191.96110 
2023-02-23
2022-12-314.683.61-1.0722 
2022-11-03
2022-09-303.292.53-0.7623 
2022-08-03
2022-06-304.555.240.6915 
2022-05-04
2022-03-315.218.583.3764 
2022-02-24
2021-12-319.911.291.3914 
2021-11-04
2021-09-309.057.7-1.3514 
2021-08-05
2021-06-305.966.460.5
2021-05-06
2021-03-312.392.840.4518 
2021-02-25
2020-12-31-0.35-0.69-0.3497 
2020-10-29
2020-09-30-0.43-0.59-0.1637 
2020-08-05
2020-06-30-0.35-0.310.0411 
2020-05-07
2020-03-31-0.35-0.350.0
2020-02-26
2019-12-31-0.42-0.370.0511 
2019-11-06
2019-09-30-0.43-0.370.0613 
2019-08-07
2019-06-30-0.44-0.410.03
2019-05-08
2019-03-31-0.36-0.4-0.0411 
2019-03-06
2018-12-31-0.36-1.78-1.42394 
2018-12-07
2018-09-300-0.52-0.52

About Moderna Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Moderna earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Moderna estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Moderna fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings10 B10.5 B
Retained Earnings Total Equity21.1 B22.1 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.85)
Earnings Share
(8.73)
Revenue Per Share
8.252
Quarterly Revenue Growth
(0.35)
Return On Assets
(0.16)
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.